Victoza Detail Aid

Question 1

What percent homology is Victoza to native GLP-1?

Answer 1

97% homologous

Question 2

What percentage of total circulating native GLP-1 does GLP-1 (7-37) represent?

Answer 2

20%

Question 3

What does Victoza do in the gut?

Answer 3

slows gastric emptying

Question 4

What does Victoza do in the liver?

Answer 4

lowers hepatic glucose production

Question 5

What does Victoza do in the pancreas?

Answer 5

increases insulin secretion in an insulin dependent manner

Question 6

What is the Victoza 3-for-1 benefit?

Answer 6

1. improved glycemic control (A1c, FPG, PPG)
2. Additional benefit of weight loss
3. Proven low rate of hypoglycemia

Question 7

Describe what functions GLP-1 performs after a person eats.

Answer 7

• Regulates blood glucose by slowing gastric empyting in the gut, to slow the absorption of sugars
• GLP-1 signals the pancreas to produce the appropriate amount of insulin in response to the food
• suppressess glucagon production in the alpha cells

Question 8

Why is the suppression of glucagon a key benefit of Victoza?

Answer 8

glucagon signals the liver to make stored glucose available in fasting times. Therefore, the suppression of glucagon leads to a reduction in the amount of glucose released into the bloodstream by the liver.

Question 9

Generically, what is the incretin effect?

Answer 9

the healthy body’s response to sugar from food

Question 10

When it is working normally, the incretin effect is responsible for what percent of insulin production in a glucose-dependent manner?

Answer 10

70%

Question 11

What are the 3 P’s of diabetes?

Answer 11

1. polyuria
2. polydipsia
3. polyphagia

Question 12

What is polyuria?

Answer 12

increased urination

Question 13

What is polydipsia?

Answer 13

increased thirst

Question 14

What is polyphagia?

Answer 14

increased appetitie

Question 15

What was the primary objective of LEAD 3?

Answer 15

To assess the safety and efficacy of Victoza as a monotherapy by comparing it to glimepiride.

Question 16

What was the A1c reduction from baseline in LEAD 3 for the 1.2 mg liraglutide arm, 1.8 mg liraglutide arm, and the glimepiride arm?

Answer 16

1. 2 mg liraglutide = -0.8%
2. 8 mg liraglutide = -1.1%

glimepiride = -0.5%

Question 17

In LEAD 3, what percentage of patients in the 1.2 mg liraglutide arm achieved an A1c of 7%?

Answer 17

42.8%

Question 18

In LEAD 3, what percentage of patients in the 1.8 mg liraglutide arm achieved an A1c of 7%?

Answer 18

50.9%

Question 19

In LEAD 3, what percentage in the glimepiride arm achieved an A1c of 7%?

Answer 19

27.8%

Question 20

In LEAD 4, what were the three treatment arms?

Answer 20

1. MET + rosi + liraglutide 1.2 mg
2. MET + rosi + liraglutide 1.8 mg
3. MET + rosi + placebo

Question 21

What was the primary objective of LEAD 4?

Answer 21

to assess the safety and efficacy of liraglutide when added to MET and rosiglitazone

Question 22

In LEAD 4, what was the change from in baseline in A1c for each of the 3 treatment arms?

Answer 22

1. 2 mg lira = -1.5%
2. 8 mg lira = -1.8%

placebo = -0.5%

Question 23

What percentage of patients achieved an A1c goal of 7% in each of the 3 treatment arms in LEAD 4?

Answer 23

• 1.2 mg lira = 57.5%
• 1.8 mg lira = 53.7%
• placebo = 28.1%

Question 24

What was the change in weight from baseline in each of the 3 treatment arms in LEAD 4?

Answer 24

• 1.2 mg lira = -2.2 lbs
• 1.8 mg lira = -4.4 lbs
• placebo = +1.3 lbs

Question 25

In LEAD 6, what was the primary objective?

Answer 25

to assess the safety and efficacy of liraglutide with exenatide

Question 26

What were the 2 treatment arms of LEAD 6?

Answer 26

liraglutide 1.8 mg and exenatide 10 mcg

Question 27

What was the change from baseline A1c in LEAD 6 in both treatment arms?

Answer 27

liraglutide = -1.1%

exenatide = -0.8%

Question 28

In LEAD 6, what percentage of patients in the liraglutide arm achieved an A1c of 7% compared to the exenatide arm?

Answer 28

54% vs. 43%